Public recall detail

Methadone Treatment of Opioid Dependence and Potential Risk of Lack of Effect when Switching between Different Products

medium
Recall Safety notice
Quick summary

Quick summary: Methadone Treatment of Opioid Dependence and Potential Risk of Lack of Effect when Switching between Different Products .

Recommended action

Recommended action: compare your product with the official notice and follow the instructions published by the official source.

Recall details

Quick summary: Methadone Treatment of Opioid Dependence and Potential Risk of Lack of Effect when Switching between Different Products .

Official details

Affected product details

Structured information extracted from the official recall notice. Confirm the identifiers and instructions in the original notice.

Brand

Issue

Health Canada has completed a safety review which examined how patients respond when they are switched from one methadone-containing product to another for the treatment of opioid dependence. The review found that there may be a link between switching methadone-containing products and the risk of lack of effect which may present as withdrawal symptoms. Health Canada is informing healthcare professionals of this safety issue and will be updating the product information to warn of this safety issue. * Jamp Methadone Oral Concentrate and Odan-Methadone have been authorized for use in Canada since January 2020; as of the date of this communication, they are not marketed.

Additional official information
Background{}
Companies
Audiences

Contains information licensed under the Open Government Licence – Canada. SafetyPulse is independent of the Government of Canada.

Official source Monitor products Back to recalls

Starting...

Related recalls

Similar recalls and safety notices.

Loading related recalls...